Tag: year

Operational Highlights May

Midland, Texas, June 16, 2025 (GLOBE NEWSWIRE) -- Natural Gas Services Group, Inc. (NYSE: NGS), a leading provider of natural gas compression equipment, technology, and services to the energy industry, today announced that Stephen C. Taylor has transitioned from Chairman of the Board to the role of Chairman Emeritus, effective immediately. Concurrently, the Company’s Board of Directors has appointed Donald J. Tringali as Chairman. Mr. Taylor continues his role as a director on the Company’s Board.

BOCA RATON, FL, June 16, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company” or “DeFi Dev Corp.”), the first US public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today announced its support for the launch of a new dfdvSOL / SOL liquidity pool on Orca, one of the leading Solana-native decentralized exchanges. The pool, deployed on Orca’s flagship Concentrated Liquidity Market Maker (CLMM), introduces new utility and yield opportunities for dfdvSOL holders, while contributing to long-term growth in SOL per share (SPS).

FREMONT, Calif., June 16, 2025 (GLOBE NEWSWIRE) -- Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company and the world's leading supplier of microinverter-based solar and battery systems, today announced the launch of its most powerful and versatile battery yet, the IQ^® Battery 5P™ with FlexPhase, for customers in Spain, Portugal, France, Sweden, Denmark, Belgium, and the Netherlands. The IQ Battery 5P with FlexPhase is an all-in-one AC-coupled system that delivers reliable backup power and supports both single-phase and three-phase applications, providing unmatched flexibility to meet diverse home energy needs. Enphase also launched the IQ Battery 5P with FlexPhase in Poland, Luxembourg, Germany, Austria, and Switzerland earlier this year.

MALVERN, Pa., June 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) amendment to initiate a Phase 2/3 pivotal confirmatory trial of OCU410ST, a modifier gene therapy candidate being developed for all Stargardt disease (ABCA4-associated retinopathies). The FDA previously granted Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation for OCU410ST for the treatment of ABCA4-associated retinopathies including Stargardt disease, retinitis pigmentosa 19, and cone-rod dystrophy 3.

MIAMI BEACH, Fla., June 16, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (“AirSculpt”) (NASDAQ: AIRS), a national provider of premium body contouring procedures, today announced the voluntary prepayment of $10.0 million of its outstanding term loan debt using cash on hand, following the successful completion of its offering of 3,634,000 shares of common stock, which generated net proceeds, after estimated expenses, of approximately $13.8 million. The Company noted that with this financing and assuming no significant changes in the current macroeconomic environment, it does not anticipate the need for additional material capital raises this year.

Simplified capital structure bolsters ability to rapidly meet customer demand, reduce interest expense, and increase liquidity